South Korea's GC Genome Corporation has entered into a collaboration and exclusive license agreement with MP Group in Bangkok, Thailand, to commercialise 'Genome Health' for genetic health checkups. Genome Health, a SNP genotyping service, utilising next-generation sequencing (NGS) to identify risk alleles associated with major cancer types and general diseases, has been developed by GC Genome.  

"Genome Health is actively securing a robust presence in South Korea's genetic health checkup market, with a primary focus on disease-related health assessments. With the capability to analyse 45 diseases in a single test, our service ensures efficient and accurate personalised health management," said Dr Chang-Seok Ki, MD, CEO at GC Genome.

Under the terms of the agreement, GC Genome will grant MP Group an exclusive license to commercialise Genome Health within the territory of Thailand. This collaboration includes the  transfer of essential wet lab technology and know-how required to operate a genetic laboratory within Thailand by GC Genome.

Once the technology is handed over, MP Group plans to launch the product under the name "genechecks" and initiate a marketing programme to promote it in Thailand.

Along with this collaboration, GC Genome and MP Group have inked a Memorandum of Understanding (MoU) to further their partnership in expanding the range of products developed by GC Genome. This expansion includes technology transfer and encompasses areas such as Health Checkup, Pre&Neonatal Health, Precision Oncology, and Rare Diseases within the territory of Thailand. This MoU will further help increase the strengthen its presence in the Southeast Asian healthcare market by establishing a value chain in the diagnostic field through a strategic partnership with MP Group.